A key role for AKT signaling in endocrine response is supported by the recent clinical study in which the targeting of mTOR, a downstream effector of AKT, sensitized ER+ breast cancers to aromatase inhibitors [25]. The gene discussed is CYP19A1; the disease is breast cancer.